CTOs on the Move

Morningside Manor Inc

www.morningsidemin.org

 
Morningside Ministries was created with the specific mission of caring for those who cared for us. The ministry was founded in 1961 by the Southwest Texas Conference of the United Methodist Church and joined five years later by First Presbyterian Church
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

International Health Management Inc

International Health Management Inc is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Prevention Point Philadelphia

Prevention Point Philadelphia is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Somanetics Corporation

Somanetics Corporation is a Troy, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Combe Incorporated

Like everything from Combe, this family of Brimms products is famous for quality. These products reflect the exceptionally high standards Combe holds to provide customers with complete satisfaction.

Neuralstem

Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic